These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29970540)

  • 21. Prognostic Value of
    Cheng G; Huang H
    PET Clin; 2018 Jan; 13(1):59-72. PubMed ID: 29157386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic
    Meijer TWH; de Geus-Oei LF; Visser EP; Oyen WJG; Looijen-Salamon MG; Visvikis D; Verhagen AFTM; Bussink J; Vriens D
    Radiology; 2017 May; 283(2):547-559. PubMed ID: 27846378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
    Burger IA; Casanova R; Steiger S; Husmann L; Stolzmann P; Huellner MW; Curioni A; Hillinger S; Schmidtlein CR; Soltermann A
    J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.
    Yıldırım F; Yurdakul AS; Özkaya S; Akdemir ÜÖ; Öztürk C
    Clin Respir J; 2017 Sep; 11(5):602-611. PubMed ID: 26434685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (
    Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
    Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
    Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
    J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Application of Metabolic Parameters Measured by ¹⁸F-FDG PET/CT in the Evaluation of the Prognosis of Non-small Cell Lung Cancer].
    Wang T; Wang Z
    Zhongguo Fei Ai Za Zhi; 2019 Mar; 22(3):167-172. PubMed ID: 30909997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer.
    Kurtipek E; Çayci M; Düzgün N; Esme H; Terzi Y; Bakdik S; Aygün MS; Unlü Y; Burnik C; Bekci TT
    Clin Nucl Med; 2015 Jun; 40(6):459-63. PubMed ID: 25742234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Value of (18)F-FDG PET-CT in the preoperative N staging of non-small cell lung cancer].
    Li M; Wu N; Liang Y; Zheng R; Liu Y; Zhang WJ; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):288-92. PubMed ID: 19615286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of Brain Metastases on Follow-up
    Nia ES; Garland LL; Eshghi N; Nia BB; Avery RJ; Kuo PH
    J Nucl Med Technol; 2017 Sep; 45(3):193-197. PubMed ID: 28705927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumorous tissue characterization using integrated 18F-FDG PET/dual-energy CT in lung cancer: Combining iodine enhancement and glycolytic activity.
    Martin SS; Muscogiuri E; Burchett PF; van Assen M; Tessarin G; Vogl TJ; Schoepf UJ; De Cecco CN
    Eur J Radiol; 2022 May; 150():110116. PubMed ID: 34996651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in non-small-cell lung cancer.
    Sharma A; Mohan A; Bhalla AS; Vishnubhatla S; Pandey AK; Bal CS; Kumar R
    Nucl Med Commun; 2017 Oct; 38(10):858-867. PubMed ID: 28817456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG-PET-based differential uptake volume histograms: a possible approach towards definition of biological target volumes.
    Devic S; Mohammed H; Tomic N; Aldelaijan S; De Blois F; Seuntjens J; Lehnert S; Faria S
    Br J Radiol; 2016 Jun; 89(1062):20150388. PubMed ID: 27007269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.
    Zhu X; Liao C; Penney BC; Li F; Ferguson MK; Simon CA; Wu T; Liu H; Pu Y
    Nucl Med Commun; 2017 Feb; 38(2):185-192. PubMed ID: 27922540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delineation of lung cancer with FDG PET/CT during radiation therapy.
    Ganem J; Thureau S; Gardin I; Modzelewski R; Hapdey S; Vera P
    Radiat Oncol; 2018 Nov; 13(1):219. PubMed ID: 30419929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
    Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
    Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.